An Open Label, Multi-center, Phase IV Roll-over Protocol for Patients Who Have Completed a Prior Global Novartis or Incyte Sponsored Ruxolitinib (INC424) Study and Are Judged by the Investigator to Benefit From Continued Treatment
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Splenomegaly
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 19 Jul 2017 Planned End Date changed from 14 Sep 2021 to 15 Sep 2021.
- 19 Jul 2017 Planned primary completion date changed from 14 Sep 2021 to 15 Sep 2021.
- 07 Apr 2017 Planned End Date changed from 1 Sep 2020 to 13 Sep 2021.